CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Jun. 27, 2020	Jun. 29, 2019
Cash Flows from Operating Activities:
Net income (loss)	$ 10,527	$ (8,479)
Non-cash items:
Depreciation and amortization	20,724	27,437
Impairment of assets	1,028	48,721
Share-based compensation expense	6,167	4,730
Deferred tax benefit	(501)	(5,309)
Provision for losses on accounts receivable and inventory	1,193	(1,378)
Other non-cash operating activities	66	50
Change in operating assets and liabilities:
Change in accounts receivable	25,067	22,518
Change in inventories	(24,557)	(37,414)
Change in prepaid income taxes	(3,544)	(3,228)
Change in other assets and other liabilities	865	(8,208)
Change in accounts payable and accrued expenses	(25,223)	(36,812)
Net cash provided by operating activities	11,812	2,628
Cash Flows from Investing Activities:
Capital expenditures	(7,696)	(8,249)
Acquisition	(16,606)	0
Proceeds from divestiture	0	9,808
Proceeds from sale of property, plant and equipment	406	302
Net cash (used in) provided by investing activities	(23,896)	1,861
Cash Flows from Financing Activities:
Net increase in short-term loans	150,000	90,000
Repayment of term loan borrowings	(4,375)	(4,375)
Share repurchases	0	(75,000)
Proceeds from employee stock purchase plan	2,144	1,830
Proceeds from exercise of stock options	1,193	3,635
Other	(11)	0
Net cash provided by financing activities	148,951	16,090
Effect of exchange rates on cash and cash equivalents	1,547	304
Net Change in Cash and Cash Equivalents	138,414	20,883
Cash and Cash Equivalents at Beginning of Period	137,311	169,351
Cash and Cash Equivalents at End of Period	275,725	190,234
Supplemental Disclosures of Cash Flow Information:
Interest paid	2,780	3,535
Income taxes paid	2,063	3,078
Transfers from inventory to fixed assets for placement of Haemonetics equipment	$ 2,364	$ 2,973